SiteOne Therapeutics Announces a $100 Million Series C Financing to Advance Selective Ion Channel Modulators as Non-opioid Treatments for Pain
December 18, 2024 07:00 AM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions, today announced a…